Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
XKH-002 by Suzhou xinkanghe Biomedical Technology for Solid Tumor: Likelihood of Approval
XKH-002 is under clinical development by Suzhou xinkanghe Biomedical Technology and currently in Phase I for Solid Tumor. According to...